|
US2013116277A1
|
|
Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
|
|
US2013034562A1
|
|
Selective androgen receptor modulators for treating diabetes
|
|
US2012157539A1
|
|
Nuclear receptor binding agents
|
|
US2012077845A1
|
|
Estrogen receptor ligands and methods of use thereof
|
|
US2012022121A1
|
|
Indoles, derivatives and analogs thereof and uses therefor
|
|
US2011237664A1
|
|
Selective androgen receptor modulators for treating diabetes
|
|
US2011172302A1
|
|
Methods of treating meibomian gland dysfunction
|
|
US2010249228A1
|
|
SARMs and method of use thereof
|
|
US2010267773A1
|
|
Estrogen receptor ligands and methods of use thereof
|
|
US2010137430A1
|
|
Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
|
|
US2009264534A1
|
|
Selective androgen receptor modulators
|
|
US2007265296A1
|
|
Nuclear receptor binding agents
|
|
US2007281906A1
|
|
Selective androgen receptor modulators for treating diabetes
|
|
US2007161608A1
|
|
Selective androgen receptor modulators for treating muscle wasting
|
|
US2007173546A1
|
|
Selective androgen receptor modulators and method of use thereof
|
|
US2006276539A1
|
|
Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
|
|
WO2005113565A2
|
|
Metabolites of selective androgen receptor modulators and methods of use thereof
|
|
US2006004042A1
|
|
Formulations comprising selective androgen receptor modulators
|
|
US2006035966A1
|
|
Irreversible selective androgen receptor modulators and methods of use thereof
|
|
US2760076A
|
|
Arrangement for minimizing negative signals
|
